Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 6/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23619333 | 0.95 | CYP19A1 (0.38) | CYP19A1HSP90AB1HDAC1HRH4HRH3 | |
| SCHEMBL20857563 | 0.83 | CYP19A1 (0.36) | CYP19A1HSP90AB1HDAC1HRH4HRH3 | |
| SCHEMBL21671069 | 0.83 | GBA1 (0.44) | CYP19A1HRH4HRH3FOLH1 | |
| SCHEMBL3435467 | 0.83 | HRH4 (0.44) | CYP19A1HSP90AB1HRH4HRH3L3MBTL1 | |
| SCHEMBL3435906 | 0.83 | CYP19A1 (0.42) | CYP19A1HSP90AB1HDAC1HRH4HRH3 | |
| SCHEMBL20364736 | 0.83 | HRH4 (0.47) | CYP19A1HSP90AB1HRH4HRH3FOLH1 | |
| SCHEMBL3435452 | 0.83 | HRH4 (0.47) | CYP19A1HSP90AB1HRH4HRH3FOLH1 | |
| SCHEMBL12278159 | 0.83 | CYP19A1 (0.46) | CYP19A1HSP90AB1HRH4HRH3L3MBTL1 | |
| SCHEMBL22794495 | 0.81 | CYP19A1 (0.44) | CYP19A1HSP90AB1HRH4HRH3L3MBTL1 | |
| SCHEMBL25468343 | 0.81 | CYP19A1 (0.44) | CYP19A1HSP90AB1HRH4HRH3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10471120-B2 | Peptidomimetic macrocycles and uses thereof | AILERON THERAPEUTICS, INC. (US) | 2019-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10471120-B2 | Peptidomimetic macrocycles and uses thereof | TP53, TP53BP1, MDM2 | CYP19A1 939/4885HSP90AB1 194/4885HDAC1 381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.